The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Structural considerations in the interaction of DNA and acridines
Lerman, L. S. (1961) · Journal of Molecular Biology · doi:10.1016/s0022-2836(61)80004-1 · Cited by 2,243
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
Mammalian SIRT1 Represses Forkhead Transcription Factors
Motta, M. C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma, Y., McBurney, M., & Guarente, L. (2004) · Cell · doi:10.1016/s0092-8674(04)00126-6 · Cited by 1,357
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.031 · Cited by 916
Purification, molecular cloning, and expression of the mammalian sigma1-binding site.
Hanner, M., Moebius, F. F., Flandorfer, A., Knaus, H. G., Striessnig, J., Kempner, E., & Glossmann, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.8072 · Cited by 911
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818
Sauve, A. A., Wolberger, C., Schramm, V. L., & Boeke, J. D. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133500 · Cited by 763
A proposal for the classification of sigma binding sites
Quirion, R., Bowen, W. D., Itzhak, Y., Junien, J. L., Musacchio, J., Rothman, R. B., Tsung-Ping, S., Tam, S. W., & Taylor, D. P. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90030-a · Cited by 755
THE STRUCTURE OF THE DNA-ACRIDINE COMPLEX
Lerman, L. S. (1963) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.49.1.94 · Cited by 722
Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
Epigenetics and aging: the targets and the marks
Fraga, M. F., & Esteller, M. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.05.008 · Cited by 690
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
Theo Cuypers, H., Selten, G., Quint, W., Zijlstra, M., Maandag, E. R., Boelens, W., van Wezenbeek, P., Melief, C., & Berns, A. (1984) · Cell · doi:10.1016/0092-8674(84)90309-x · Cited by 639
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Discovery and development of SAHA as an anticancer agent
Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210204 · Cited by 626
From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
de Sa Alves, F., Barreiro, E., & Manssour Fraga, C. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788452649 · Cited by 604
Staker, B. L., Feese, M. D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., & Burgin, A. B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049146p · Cited by 546
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1
Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.-F., Barker, J., Yau, W. T., Amouzegh, P., Flegg, A., Hamelin, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050522v · Cited by 523
Current developments of coumarin-based anti-cancer agents in medicinal chemistry
Emami, S., & Dadashpour, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.033 · Cited by 504
Self-citationSigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.
Vilner, B. J., John, C. S., & Bowen, W. D. (1995) · PubMed · Cited by 482
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
The sigma-1 receptor chaperone as an inter-organelle signaling modulator
Su, T.-P., Hayashi, T., Maurice, T., Buch, S., & Ruoho, A. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.007 · Cited by 466
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Genomewide studies of histone deacetylase function in yeast
Bernstein, B. E., Tong, J. K., & Schreiber, S. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250477697 · Cited by 421
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
The survival kinases Akt and Pim as potential pharmacological targets
Amaravadi, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26273 · Cited by 408
Wang, A. H. J., Ughetto, G., Quigley, G. J., & Rich, A. (1987) · Biochemistry · doi:10.1021/bi00378a025 · Cited by 405
The Sigma Receptor as a Ligand-Regulated Auxiliary Potassium Channel Subunit
Aydar, E., Palmer, C. P., Klyachko, V. A., & Jackson, M. B. (2002) · Neuron · doi:10.1016/s0896-6273(02)00677-3 · Cited by 398
The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
Liu, T., Liu, P. Y., & Marshall, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3365 · Cited by 384
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
Wall, M. E., & Wani, M. C. (1995) · PubMed · Cited by 376
Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., & Schwaller, J. (2010) · Haematologica · doi:10.3324/haematol.2009.017079 · Cited by 368
Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
Fortune, J. M., & Osheroff, N. (2000) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(00)64006-0 · Cited by 366
Bouras, T., Fu, M., Sauve, A. A., Wang, F., Quong, A. A., Perkins, N. D., Hay, R. T., Gu, W., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408748200 · Cited by 355
Mitomycin C: a clinical update
Bradner, W. T. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0202 · Cited by 346
Indole, a core nucleus for potent inhibitors of tubulin polymerization
Brancale, A., & Silvestri, R. (2007) · Medicinal Research Reviews · doi:10.1002/med.20080 · Cited by 344
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor
Fox, C. J., Hammerman, P. S., Cinalli, R. M., Master, S. R., Chodosh, L. A., & Thompson, C. B. (2003) · Genes & Development · doi:10.1101/gad.1105003 · Cited by 336
Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. E. (2003) · PubMed · Cited by 312
Indole Alkaloids from Catharanthus roseus: Bioproduction and Their Effect on Human Health
Almagro, L., Fernández-Pérez, F., & Pedreño, M. (2015) · Molecules · doi:10.3390/molecules20022973 · Cited by 291
Wang, Z., Bhattacharya, N., Weaver, M., Petersen, K., Meyer, M., Gapter, L., & Magnuson, N. S. (2001) · Journal of Veterinary Science · doi:10.4142/jvs.2001.2.3.167 · Cited by 269
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.436 · Cited by 259
Cross‐Talk between Aging and Cancer: The Epigenetic Language
FRAGA, M. F., AGRELO, R., & ESTELLER, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.005 · Cited by 251
Ostenfeld, M. S., Fehrenbacher, N., Høyer-Hansen, M., Thomsen, C., Farkas, T., & Jäättelä, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0269 · Cited by 248
Crawford, K. W., & Bowen, W. D. (2002) · PubMed · Cited by 240
Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)86002-x · Cited by 205
Indole Alkaloids from the Tunicate Aplidium meridianum
Franco, L. H., Joffé, E. B. D. K., Puricelli, L., Tatian, M., Seldes, A. M., & Palermo, J. A. (1998) · Journal of Natural Products · doi:10.1021/np970493u · Cited by 194
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002
Jacobs, M. D., Black, J., Futer, O., Swenson, L., Hare, B., Fleming, M., & Saxena, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413155200 · Cited by 192
Pogacic, V., Bullock, A. N., Fedorov, O., Filippakopoulos, P., Gasser, C., Biondi, A., Meyer-Monard, S., Knapp, S., & Schwaller, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0320 · Cited by 189
Topoisomerase Inhibitors: A Review of their Therapeutic Potential in Cancer
Sinha, B. K. (1995) · Drugs · doi:10.2165/00003495-199549010-00002 · Cited by 178
Moore, M. H., Hunter, W. N., d'Estaintot, B. L., & Kennard, O. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90577-9 · Cited by 168
Sirtuin 1 (SIRT1): The Misunderstood HDAC
Stünkel, W., & Campbell, R. M. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111422103 · Cited by 164
Antioxidant activity of unexplored indole derivatives: Synthesis and screening
Estevão, M. S., Carvalho, L. C., Ribeiro, D., Couto, D., Freitas, M., Gomes, A., Ferreira, L. M., Fernandes, E., & Marques, M. M. B. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.07.059 · Cited by 163
Grundler, R., Brault, L., Gasser, C., Bullock, A. N., Dechow, T. N., Woetzel, S., Pogačić, V., Villa, A., Ehret, S., Berridge, G., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082074 · Cited by 162
Sherer, C., & Snape, T. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.007 · Cited by 160
Bullock, A. N., Debreczeni, J. E., Fedorov, O., Nelson, A. S., Marsden, B. D., & Knapp, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0504858 · Cited by 157
Mumenthaler, S. M., Ng, P. Y. B., Hodge, A., Bearss, D. J., Berk, G., Kanekal, S., Redkar, S., Taverna, P., Agus, D. B., & Jain, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0293 · Cited by 154
Structural Features Important for .sigma.1 Receptor Binding
Glennon, R. A., Ablordeppey, S. Y., Ismaiel, A. M., El‐Ashmawy, M. B., Fischer, J. B., & Howie, K. B. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00034a020 · Cited by 147
Novotny‐Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 141
Samosorn, S., Bremner, J. B., Ball, A. R., & Lewis, K. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.019 · Cited by 137
Madadkar‐Sobhani, A., Ebrahimi, S.-A., & Mahmoudian, M. (2002) · PubMed · Cited by 134
Remiszewski, S., Sambucetti, L. C., Bair, K. W., Bontempo, J., Cesarz, D., Chandramouli, N., Chen, R., Cheung, M., Cornell-Kennon, S., Dean, K., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030235w · Cited by 130
Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
Mahajan, S. S., Scian, M., Sripathy, S. P., Posakony, J., Lao, U., Loe, T. K., Leko, V., Thalhofer, A., Schuler, A. D., Bedalov, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4018064 · Cited by 126
Bono, J. S. D., Kristeleit, R. S., Tolcher, A. W., Fong, P. C. C., Pacey, S., Karavasilis, V., Mita, M. M., Shaw, H. M., Workman, P., Kaye, S. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0376 · Cited by 126
Medda, F., Russell, R. J. M., Higgins, M., McCarthy, A. R., Campbell, J., Slawin, A. M. Z., Lane, D. P., Laín, S., & Westwood, N. J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8014298 · Cited by 124
Furlan, A., Monzani, V., Reznikov, L. L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., & Dinarello, C. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00020 · Cited by 120
Inhibition of type II topoisomerase by fostriecin
Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R., & Fry, D. W. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90096-2 · Cited by 118
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111
Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety
Nasab, S. G., Khoobi, M., Hadizadeh, F., Marjani, A., Moradi, A., Nadri, H., Emami, S., Foroumadi, A., & Shafiee, A. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.014 · Cited by 111
Self-citationVillard, V., Espallergues, J., Keller, E., Alkam, T., Nitta, A., Yamada, K., Nabeshima, T., Vamvakides, A., & Maurice, T. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.212 · Cited by 107
Mirzaei, H., & Emami, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.067 · Cited by 105
Self-citationSigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands
van Waarde, A., Rybczynska, A. A., Ramakrishnan, N. K., Ishiwata, K., Elsinga, P. H., & Dierckx, R. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793563365 · Cited by 103
Akrami, H., Mirjalili, B. F., Khoobi, M., Nadri, H., Moradi, A., Sakhteman, A., Emami, S., Foroumadi, A., & Shafiee, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.017 · Cited by 99
Self-citationAkué‐Gédu, R., Rossignol, E., Azzaro, S., Knapp, S., Filippakopoulos, P., Bullock, A. N., Bain, J., Cohen, P., Prudhomme, M., Anizon, F., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901018f · Cited by 99
Sigma-2 ligands induce tumour cell death by multiple signalling pathways
Zeng, C., Rothfuss, J., Zhang, J., Chu, W., Vangveravong, S., Tu, Z., Pan, F., Chang, K. C., Hotchkiss, R., & Mach, R. H. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.602 · Cited by 94
Wang, H., Yu, N., Chen, D., Lee, K. C. L., Lye, P. L., Chang, J. W. W., Deng, W., Ng, M., Lu, T., Khoo, M. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2003552 · Cited by 94
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor
Haddach, M., Michaux, J., Schwaebe, M. K., Pierre, F., O’Brien, S., Borsan, C., Tran, J. A., Raffaele, N., Ravula, S., Drygin, D., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200259q · Cited by 93
Hyrtinadine A, a Bis-indole Alkaloid from a Marine Sponge
Endo, T., Tsuda, M., Fromont, J., & Kobayashi, J. (2006) · Journal of Natural Products · doi:10.1021/np060420n · Cited by 92
Alcain, F. J., & Villalba, J. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902755111 · Cited by 90
Yu, L. J., Wu, H.-S., Tang, L., Feng, C.-R., Yu, J.-H., Yu, L. J., Yu, Y., Yang, B., & He, Q. W. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.08.002 · Cited by 89
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer
Moore, R. L., Dai, Y., & Faller, D. V. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0217 · Cited by 88
Antiproliferative Effect of Indole Phytoalexins
Chripková, M., Zigo, F., & Mojžíš, J. (2016) · Molecules · doi:10.3390/molecules21121626 · Cited by 82
Santio, N. M., Vahakoski, R. L., Rainio, E.-M., Sandholm, J. A., Virtanen, S. S., Prudhomme, M., Anizon, F., Moreau, P., & Koskinen, P. J. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-279 · Cited by 81
SIRT1 Modulation as a Novel Approach to the Treatment of Diseases of Aging
Blum, C. A., Ellis, J. L., Loh, C., Ng, P. Y., Perni, R. B., & Stein, R. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100861p · Cited by 79
Sigma Receptors: Chemistry, Cell Biology And Clinical Implications
Matsumoto, R. R. (2007) · Medical Entomology and Zoology · Cited by 78
The anticancer drug–DNA complex: Femtosecond primary dynamics for anthracycline antibiotics function
Qu, X., Wan, C., Becker, H.-D., Zhong, D., & Zewail, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241509698 · Cited by 76
Li, X., Inks, E. S., Li, X., Hou, J., Chou, C. J., Zhang, J., Jiang, Y., Zhang, Y., & Xu, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401877m · Cited by 76
Lai, M.-J., Huang, H.-L., Pan, S., Liu, Y.-M., Peng, C.-Y., Lee, H., Yeh, T., Huang, P.-H., Teng, C., Chen, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300197a · Cited by 72
Clinical Trials with Sigma Ligands
Volz, H., & Stoll, K.-D. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832680 · Cited by 69
Mahboobi, S., Sellmer, A., Höcher, H., Garhammer, C., Pongratz, H., Maier, T. M., Ciossek, T., & Beckers, T. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703136 · Cited by 68
Queiroz, M. J. R. P., Abreu, A. S. L. M., Carvalho, M. S. D., Ferreira, P. M. T., Nazareth, N., & Nascimento, M. S.-J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.04.004 · Cited by 67
Panathur, N., Gokhale, N., Dalimba, U., Pulla, V. K., Yogeeswari, P., & Sriram, D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.015 · Cited by 59
New indole-based chalconoids as tubulin-targeting antiproliferative agents
Mirzaei, H., Shokrzadeh, M., Modanloo, M., Ziar, A., Riazi, G. H., & Emami, S. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.09.005 · Cited by 57
Self-citationRobust scoring functions for protein-ligand interactions with quantum chemical charge models.
Wang, J.-C., Lin, J.-H., Chen, C.-M., Perryman, A. L., & Olson, A. J. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200220v · Cited by 54
Age-Related Changes in Melatonin Release in the Murine Distal Colon
Diss, L. B., Robinson, S. D., Wu, Y., Fidalgo, S., Yeoman, M. S., & Patel, B. A. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn4000617 · Cited by 54
Giannini, G., Marzi, M., Marzo, M. D., Battistuzzi, G., Pezzi, R., Brunetti, T., Cabri, W., Vesci, L., & Pisano, C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.101 · Cited by 53
Amiloride derived inhibitors of acid-sensing ion channel-3 (ASIC3)
Kuduk, S. D., Marco, C. N. D., Chang, R. K., DiPardo, R. M., Cook, S. P., Cato, M. J., Jovanovska, A., Urban, M. O., Leitl, M. D., Spencer, R. H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.029 · Cited by 53
Mehndiratta, S., Hsieh, Y.-L., Liu, Y.-M., Wang, A. W., Lee, H., Liang, L., Kumar, S., Teng, C., Yang, C., & Liou, J. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.020 · Cited by 52
The Selective ς2-Ligand Lu 28-179 Has Potent Anxiolytic-Like Effects in Rodents
Sánchez, C., Arnt, J., Costall, B., Kelly, M. E., Meier, E., Naylor, R. J., & Perregaard, J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37124-1 · Cited by 51
Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3)
Kuduk, S. D., Chang, R. K., Wai, J., Marco, C. N. D., Cofre, V., DiPardo, R. M., Cook, S. P., Cato, M. J., Jovanovska, A., Urban, M. O., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.021 · Cited by 49
Zhang, Y., Yang, P., Chou, C. J., Liu, C., Wang, X., & Xu, W. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300366t · Cited by 48
Novel indolyl-pyrimidine derivatives: synthesis, antimicrobial, and antioxidant evaluations
Mohamed, M. S., Youns, M., & Ahmed, N. M. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-0916-1 · Cited by 44
Human SIRT1: A potential biomarker for tumorigenesis?
Lim, C. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.003 · Cited by 43
Chang, S., Christian, W., Wu, M.-H., Chen, T., Lin, Y.-W., Suen, C., Pidugu, H. B., Detroja, D., Shah, A. K., Hwang, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.046 · Cited by 42
Abate, C., Perrone, R., & Berardi, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436485 · Cited by 41
Panathur, N., Dalimba, U., Pulla, V. K., Alvala, M., Yogeeswari, P., Sriram, D., & Kumar, V. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.08.018 · Cited by 36
Fouliard, S., Robert, R., Jacquet-Bescond, A., du Rieu, Q. C., Balasubramanian, S., Loury, D. J., Loriot, Y., Hollebecque, A., Kloos, I., Soria, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.009 · Cited by 34
Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors
Wu, B., Wang, H., Cee, V. J., Lanman, B. A., Nixey, T. E., Pettus, L. H., Reed, A. B., Wurz, R. P., Guerrero, N. T., Sastri, C. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.091 · Cited by 33
Cai, M., Hu, J., Tian, J., Yan, H., Zheng, C., & Hu, W. (2015) · Chinese Chemical Letters · doi:10.1016/j.cclet.2015.03.015 · Cited by 32
Layek, M., Kumar, Y., Islam, A., Karavarapu, R., Sengupta, A., Halder, D., Mukkanti, K., & Pal, M. (2011) · MedChemComm · doi:10.1039/c1md00029b · Cited by 28
Freitag, M., Schemies, J., Larsen, T., Gaghlab, K. E., Schulz, F., Rumpf, T., Jung, M., & Link, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.026 · Cited by 27
Jiao, J., Fang, H., Wang, X., Guan, P. F., Yuan, Y., & Xu, W. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.06.010 · Cited by 24
Pim family of protein kinases: Structure, functions, and roles in hematopoietic malignancies
Zhukova, Y. N., Alekseeva, M. G., Zakharevich, N. V., Shtil, A. A., & Даниленко, В. Н. (2011) · Molecular Biology · doi:10.1134/s0026893311040170 · Cited by 22
Chen, C., Wu, M.-H., Chen, Y., Yen, T.-Y., Lin, Y., Chao, S.-H., Tala, S. D., Tsai, T., Su, T., & Lee, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.005 · Cited by 22
Wang, X., Li, X., Li, J., Hou, J., Qu, Y., Yu, C., He, F., Xu, W., & Wu, J. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12819 · Cited by 22
Targets in anticancer research--A review.
Jayashree, B., Nigam, S., Pai, A., Patel, H., Reddy, N. D., Kumar, N., & Cm, R. (2015) · PubMed · Cited by 21
Synthesis and in vitro Evaluation of Novel Indole‐Based Sigma Receptors Ligands
Yarım, M., Köksal, M., Schepmann, D., & Wünsch, B. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01215.x · Cited by 18
Discovery of a series of small molecules as potent histone deacetylase inhibitors
Zhang, L., Wang, X., Li, X., & Xu, W. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.780237 · Cited by 12
(1997) · PubMed
Cited by
Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives
Kumari, A., & Singh, R. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103021 · Cited by 583
Indole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
Chalcone Derivatives: Role in Anticancer Therapy
Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021) · Biomolecules · doi:10.3390/biom11060894 · Cited by 399
Pyrolysis of microalgae: A critical review
Yang, C., Li, R., Zhang, B., Qiu, Q., Wang, B., Yang, H., Ding, Y., & Wang, C. (2019) · Fuel Processing Technology · doi:10.1016/j.fuproc.2018.12.012 · Cited by 345
Pandurang, T. P., Kumar, B., Verma, N., Dastidar, D. G., Yamada, R., Nishihara, T., Tanabe, K., & Kumar, D. (2023) · ChemMedChem · doi:10.1002/cmdc.202200405 · Cited by 8
Metadata
- Authors
- Dadashpour, S., & Emami, S.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 150
- Pages
- 9-29
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2794119433
- Cited by
- 343
- References
- 134
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.